Canagliflozin in Advanced Renal Disease With MRI Endpoints
Status:
Recruiting
Trial end date:
2029-03-30
Target enrollment:
Participant gender:
Summary
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial,
assessing the effect of canagliflozin on cardiac structure and function in patients with
advanced renal disease, including those on maintenance dialysis.
Our primary aim is to determine the effect of canagliflozin on cardiac structure and function
in patients with advanced chronic kidney disease (CKD), compared with placebo. We hypothesize
that canagliflozin will improve left ventricular (LV) hypertrophy in patients with advanced
CKD. Our secondary aims are to describe the effect of canagliflozin on other cardiac magnetic
resonance imaging parameters and surrogate markers of efficacy in this population.
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre